Barclays Upgrades Mylan (MYL) to Overweight, Sees Approval for Generic Copaxone
Tweet Send to a Friend
Barclays upgraded Mylan (NASDAQ: MYL) from Equalweight to Overweight with a price target of $50.00 (from $47.00).Analyst Douglas Tsao notes ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
